Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

bluebird bio : Announces September Investor Events

09/02/2020 | 08:08am EDT

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

  • 2020 Wells Fargo Virtual Healthcare Conference, Thursday, September 10, at 4:00 pm ET
  • Morgan Stanley 18th Annual Global Healthcare Conference, Tuesday, September 15, at 1:15 pm ET
  • BofA Global Healthcare Conference 2020, Friday, September 18, at 10:05 am ET

To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.


© Business Wire 2020
All news about BLUEBIRD BIO, INC.
06/11BLUEBIRD BIO INVESTIGATION INITIATED : Kahn Swick & Foti, LLC Investigates the O..
BU
06/11BLUEBIRD BIO  : Across Phase 3 studies, 89% (32/36) of evaluable patients across..
PU
06/11BLUEBIRD BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/11BLUEBIRD BIO  : betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for &b..
BU
06/07BLUEBIRD BIO  : to Present at Goldman Sachs Global Healthcare Conference
BU
06/07BLUEBIRD BIO  : Says FDA Has Lifted Clinical Hold For Studies Evaluating Investi..
MT
06/07BLUEBIRD BIO  : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disea..
PU
06/07BLUEBIRD BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/07BLUEBIRD BIO  : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disea..
BU
06/02INSIDER TRENDS : Bluebird Bio Insider Receives Stock Award, Buy Trend Intact
MT
More news
Financials (USD)
Sales 2021 104 M - -
Net income 2021 -831 M - -
Net cash 2021 739 M - -
P/E ratio 2021 -2,72x
Yield 2021 -
Capitalization 2 214 M 2 214 M -
EV / Sales 2021 14,2x
EV / Sales 2022 7,19x
Nbr of Employees 1 201
Free-Float 99,1%
Chart BLUEBIRD BIO, INC.
Duration : Period :
bluebird bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEBIRD BIO, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 48,73 $
Last Close Price 32,83 $
Spread / Highest target 162%
Spread / Average Target 48,4%
Spread / Lowest Target -17,8%
EPS Revisions
Managers and Directors
NameTitle
Nick Leschly President, Chief Executive Officer & Director
William Denise Baird Chief Financial & Accounting Officer
Daniel S. Lynch Chairman
Philip D. Gregory Chief Scientific Officer
Derek Adams Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO, INC.-24.13%2 214
GILEAD SCIENCES, INC.16.87%85 472
WUXI APPTEC CO., LTD.28.23%66 801
REGENERON PHARMACEUTICALS9.19%54 755
BIONTECH SE167.63%53 275
VERTEX PHARMACEUTICALS-20.04%50 427